

# CITATION REPORT

List of articles citing

**Targeting EGFR Exon 20 Insertion Mutation in  
Nonsmall cell Lung Cancer: Amivantamab and Mobocertinib**

**DOI: 10.1177/10600280221098398**

**Annals of Pharmacotherapy, , , 106002802210983.**

**Source:** <https://exaly.com/paper-pdf/146303616/citation-report.pdf>

**Version:** 2024-04-26

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
4	Discovery of mobocertinib, a new irreversible tyrosine kinase inhibitor indicated for the treatment of non-small-cell lung cancer harboring EGFR exon 20 insertion mutations. <b>2022</b> , 31, 1647-1662		0
3	Immunotherapy in Non-Small-Cell Lung Cancer Patients with Driver Alterations: A New Strategy?. <b>2022</b> , 11, 3280		0
2	New drug approvals for 2021: Synthesis and clinical applications. <b>2023</b> , 245, 114898		0
1	Precision medicine: Ray of hope in overcoming cancer multidrug resistance. <b>2022</b> , 65, 100889		0